Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Return on Equity (2018 - 2025)

X4 Pharmaceuticals' Return on Equity history spans 8 years, with the latest figure at 0.64% for Q4 2025.

  • For Q4 2025, Return on Equity rose 28.0% year-over-year to 0.64%; the TTM value through Dec 2025 reached 0.64%, up 28.0%, while the annual FY2025 figure was 0.76%, 26.0% up from the prior year.
  • Return on Equity reached 0.64% in Q4 2025 per XFOR's latest filing, up from 2.9% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.65% in Q1 2025 to a low of 7.58% in Q2 2025.
  • Average Return on Equity over 5 years is 1.73%, with a median of 1.45% recorded in 2023.
  • The largest YoY upside for Return on Equity was 559bps in 2025 against a maximum downside of -795bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 1.33% in 2021, then dropped by -4bps to 1.38% in 2022, then fell by -23bps to 1.7% in 2023, then surged by 46bps to 0.92% in 2024, then skyrocketed by 30bps to 0.64% in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Return on Equity are 0.64% (Q4 2025), 2.9% (Q3 2025), and 7.58% (Q2 2025).